Form 8-K EyePoint, Inc. For: Jul 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as tech earnings spark AI spending worries and oil hits $100
- Intel jumps 10% after AI-fueled quarter crushes estimates, upbeat outlook
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
EyePoint Pharmaceuticals settles False Claims Act case for $4.7M
July 17, 2026 4:07 PM EDTEyePoint Pharmaceuticals (NASDAQ: EYPT) has reached a settlement agreement with the U.S. Department of Justice and related federal agencies over alleged civil violations tied to the sales and marketing of its eye care product DEXYCU, which the company commercialized between 2019 and 2023.
According to a press release, the settlement, effective July 17, 2026, resolves potential claims under the False Claims Act, the Civil Monetary Penalties... More
